Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical stage biotechnology company, has announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The event is scheduled for Tuesday, September 24, 2024, at 12 PM EDT.
Mr. Robert Bitterman, CEO and Chairman of the Board, will present on behalf of Phio Pharmaceuticals. The company specializes in INTASYL® siRNA gene silencing technology, designed to enhance immune cells' effectiveness in killing tumor cells.
Stakeholders, investors, and interested individuals are invited to register and attend this live event. A replay will be available on the Renmark Financial Communications Inc. website. Attendees are advised to use the latest version of Google Chrome for optimal connectivity.
Phio Pharmaceuticals (NASDAQ: PHIO), un'azienda biotecnologica in fase clinica, ha annunciato la sua partecipazione alla Serie di Roadshow Virtuali Non-Deal di Renmark Financial Communications. L'evento è programmato per martedì 24 settembre 2024, alle 12 PM EDT.
Il signor Robert Bitterman, CEO e Presidente del Consiglio, presenterà a nome di Phio Pharmaceuticals. L'azienda è specializzata nella tecnologia di silenziamento genico INTASYL® siRNA, progettata per migliorare l’efficacia delle cellule immunitarie nell’uccidere le cellule tumorali.
Stakeholder, investitori e soggetti interessati sono invitati a registrarsi e partecipare a questo evento dal vivo. Una registrazione sarà disponibile sul sito web di Renmark Financial Communications Inc. Si consiglia ai partecipanti di utilizzare l'ultima versione di Google Chrome per una connettività ottimale.
Phio Pharmaceuticals (NASDAQ: PHIO), una empresa biotecnológica en etapa clínica, ha anunciado su participación en la Serie de Roadshow Virtuales No-Deal de Renmark Financial Communications. El evento está programado para el martes 24 de septiembre de 2024, a las 12 PM EDT.
El Sr. Robert Bitterman, CEO y Presidente de la Junta, presentará en nombre de Phio Pharmaceuticals. La empresa se especializa en la tecnología de silenciamiento génico INTASYL® siRNA, diseñada para mejorar la efectividad de las células inmunitarias en la eliminación de células tumorales.
Se invita a las partes interesadas, inversionistas e individuos interesados a registrarse y asistir a este evento en vivo. Una repetición estará disponible en el sitio web de Renmark Financial Communications Inc. Se aconseja a los asistentes usar la última versión de Google Chrome para una conectividad óptima.
Phio Pharmaceuticals (NASDAQ: PHIO), 임상 단계 생명공학 회사가 Renmark Financial Communications 가상 비거래 로드쇼 시리즈에 참여한다고 발표했습니다. 이 행사는 2024년 9월 24일 화요일, 오후 12시 EDT에 예정되어 있습니다.
로버트 비터맨 CEO 겸 이사회 의장이 Phio Pharmaceuticals를 대신해 발표할 것입니다. 이 회사는 종양 세포를 죽이는 면역 세포의 효과를 향상시키기 위해 설계된 INTASYL® siRNA 유전자 침묵 기술을 전문으로 합니다.
이해관계자, 투자자 및 관심 있는 개인들은 등록하여 이 라이브 이벤트에 참석하도록 초대됩니다. 재생이 Renmark Financial Communications Inc. 웹사이트에 제공됩니다. 참석자는 원활한 연결을 위해 최신 버전의 Google Chrome을 사용할 것을 권장합니다.
Phio Pharmaceuticals (NASDAQ: PHIO), une entreprise de biotechnologie en phase clinique, a annoncé sa participation à la Série de Roadshow Virtuels Non-Deal de Renmark Financial Communications. L'événement est prévu pour mardi 24 septembre 2024, à 12 heures EDT.
M. Robert Bitterman, PDG et Président du conseil, présentera au nom de Phio Pharmaceuticals. L'entreprise est spécialisée dans la technologie de suspension génique INTASYL® siRNA, conçue pour améliorer l'efficacité des cellules immunitaires dans la destruction des cellules tumorales.
Les parties prenantes, les investisseurs et les personnes intéressées sont invitées à s'inscrire et à assister à cet événement en direct. Un replay sera disponible sur le site de Renmark Financial Communications Inc. Il est conseillé aux participants d'utiliser la dernière version de Google Chrome pour une connectivité optimale.
Phio Pharmaceuticals (NASDAQ: PHIO), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an der Virtuellen Non-Deal Roadshow-Serie von Renmark Financial Communications bekannt gegeben. Die Veranstaltung ist für Dienstag, den 24. September 2024, um 12 Uhr EDT angesetzt.
Herr Robert Bitterman, CEO und Vorsitzender des Vorstands, wird im Namen von Phio Pharmaceuticals präsentieren. Das Unternehmen ist auf die INTASYL® siRNA-Genschneidetechnologie spezialisiert, die darauf abzielt, die Effektivität von Immunzellen beim Töten von Tumorzellen zu steigern.
Stakeholder, Investoren und Interessierte sind eingeladen, sich zu registrieren und an dieser Live-Veranstaltung teilzunehmen. Eine Aufzeichnung wird auf der Website von Renmark Financial Communications Inc. zur Verfügung stehen. Es wird empfohlen, die neueste Version von Google Chrome für eine optimale Konnektivität zu verwenden.
- None.
- None.
Presentation and live Q&A to take place Tuesday, September 24, 2024, at 12 PM EDT
Marlborough, Massachusetts--(Newsfile Corp. - September 17, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc.
Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present on Tuesday, September 24, 2024, at 12 PM EDT. A replay of the event may be accessed on the Renmark Financial Communications Inc. website at https://www.renmarkfinancial.com/vndrs.
Phio Pharmaceuticals welcomes stakeholders, investors, and other individual followers to register and attend this live event.
REGISTER HERE: https://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-nasdaq-phio-N0AOK-Jkr-
To ensure smooth connectivity, please access the link above using the latest version of Google Chrome.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical stage biotechnology company whose proprietary technology, INTASYL, precisely silences virtually any gene in the human genome. In addition to targeting solid tumors, INTASYL can effectively enhance applications in adoptive cell therapy.
For additional information, visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
Renmark Financial Communications Inc.
James R. Kautz: jkautz@renmarkfinancial.com
Tel: (416)-644-2020 or (212)-812-7680
www.renmarkfinancial.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/223013
FAQ
When is Phio Pharmaceuticals participating in the Renmark Financial Communications Virtual Non-Deal Roadshow?
Who will be presenting for Phio Pharmaceuticals (PHIO) at the Virtual Non-Deal Roadshow?
What is the main focus of Phio Pharmaceuticals' (PHIO) technology?
How can interested parties attend Phio Pharmaceuticals' (PHIO) Virtual Non-Deal Roadshow presentation?
Will there be a replay available for Phio Pharmaceuticals' (PHIO) Virtual Non-Deal Roadshow presentation?
